Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Nuvalent (NUVL)
NASDAQ:NUVL
Nuvalent (NUVL) Stock Price & Analysis
48 Followers
NUVL Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$39.86 - $89.39
Previous Close$80.3
Volume263.41K
Average Volume (3M)384.41K
Market Cap
$5.18B
Enterprise Value$4.49B
Total Cash (Recent Filing)$691.84M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.63
Next Earnings
Aug 08, 2024EPS Estimate
-$0.76Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.41
Shares Outstanding64,556,130
10 Day Avg. Volume352,118
30 Day Avg. Volume384,406
Standard Deviation0.28
R-Squared0.06
Alpha0.06
Financial Highlights & Ratios
Price to Book (P/B)7.30
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-42.30
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-37.18
Forecast
1Y Price Target
$102.25Price Target Upside27.89% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
Nuvalent News
Bulls Say, Bears Say
Bulls Say
Drug EfficacyNVL-655 demonstrates robust efficacy with an overall response rate of 54% in patients with ALK resistance mutations, and strong central nervous system activity with a response rate of 52% in patients with CNS metastases.
Market PotentialAnalyst upgrades NVL to Outperform with expectations of NVL-655 becoming a multiblockbuster lung cancer agent, potentially achieving peak sales of around $6.1bn in ALK+ NSCLC across lines.
Safety And TolerabilityThe safety profile of NVL-655 is relatively clean, showing promise with low percentages of serious liver enzyme increases, avoidance of TRK-related adverse events, and very few dose discontinuations and reductions.
Bears Say
Drug EfficacyNVL-655 needs to demonstrate better survival outcomes to effectively penetrate the market.
EarningsNUVL reported a significant net loss.
Market CompetitionSurveyed physicians anticipate Alecensa to maintain its lead in the market following potential approvals.
---
Ownership Overview
43.44% Insiders
22.72% Mutual Funds
11.03% Other Institutional Investors
22.81% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
NUVL FAQ
What was Nuvalent’s price range in the past 12 months?
Nuvalent lowest stock price was $39.86 and its highest was $89.39 in the past 12 months.
What is Nuvalent’s market cap?
Currently, no data Available
When is Nuvalent’s upcoming earnings report date?
Nuvalent’s upcoming earnings report date is Aug 08, 2024 which is in 13 days.
How were Nuvalent’s earnings last quarter?
Nuvalent released its earnings results on May 09, 2024. The company reported -$0.69 earnings per share for the quarter, missing the consensus estimate of -$0.663 by -$0.027.
Is Nuvalent overvalued?
According to Wall Street analysts Nuvalent’s price is currently Undervalued.
Does Nuvalent pay dividends?
Nuvalent does not currently pay dividends.
What is Nuvalent’s EPS estimate?
Nuvalent’s EPS estimate is -$0.76.
How many shares outstanding does Nuvalent have?
Nuvalent has 59,120,876 shares outstanding.
What happened to Nuvalent’s price movement after its last earnings report?
Nuvalent reported an EPS of -$0.69 in its last earnings report, missing expectations of -$0.663. Following the earnings report the stock price went down -0.03%.
Which hedge fund is a major shareholder of Nuvalent?
Among the largest hedge funds holding Nuvalent’s share is Deerfield Management Company, LP. It holds Nuvalent’s shares valued at 2B.
---
Nuvalent Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$102.25 (27.89% Upside)
$102.25 (27.89% Upside)
Blogger Sentiment
Bullish
NUVL Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Decreased
By 398.5K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 2.8%
Last 30 Days ▲ 14.1%
Last 30 Days ▲ 14.1%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
74.52%
12-Months-Change
Fundamentals
Return on Equity
-26.01%
Trailing 12-Months
Asset Growth
53.68%
Trailing 12-Months
Company Description
Nuvalent
Nuvalent Inc is a biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer, designed to overcome the limitations of existing therapies for clinically proven kinase targets.
---
NUVL Stock 12 Month Forecast
Average Price Target
$102.25
▲(27.89% Upside)
Technical Analysis
Intellia Therapeutics
―
Crispr Therapeutics AG
―
Editas Medicine
―
Beam Therapeutics
―
Best Analysts Covering NUVL
1 Year
1 Year Success Rate
5/5 ratings generated profit
1 Year Average Return
+33.14%
reiterated a buy rating 16 days ago
Copying Bradley Canino's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +33.14% per trade.
---